SCHEMBL3070448

SCHEMBL3070448

CC1CCCN(c2c(C(=O)O)cnn2-c2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.52
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
NR4A3 Q92570 1/20 0.46
TP53 P04637 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
RIPK2 O43353 1/20 0.42
ATM Q13315 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3067178 0.87 L3MBTL1 (0.53) MAPTRAB9ANPC1L3MBTL1KEAP1
SCHEMBL27783371 0.84 L3MBTL1 (0.50) MAPTRAB9ANPC1L3MBTL1KEAP1
SCHEMBL3068285 0.83 L3MBTL1 (0.64) MAPTRAB9ANPC1L3MBTL1KEAP1
SCHEMBL3063126 0.83 HSD11B1 (0.52) MAPTRAB9ANPC1
SCHEMBL3063443 0.82 L3MBTL1 (0.62) MAPTRAB9ANPC1L3MBTL1KEAP1
SCHEMBL3686491 0.82 CASR (0.47) MAPTRAB9ANPC1KDM4EALDH1A1
SCHEMBL3075062 0.81 L3MBTL1 (0.56) MAPTL3MBTL1KEAP1NFE2L2NR4A3
SCHEMBL3081434 0.81 L3MBTL1 (0.54) MAPTL3MBTL1KEAP1NFE2L2NR4A3
SCHEMBL27783409 0.79 L3MBTL1 (0.56) MAPTL3MBTL1KEAP1NFE2L2NR4A3
SCHEMBL13962616 0.79 MAPT (0.44) MAPTRAB9ANPC1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101743226-B Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2012-10-10 CN claimed
CN-101743226-A Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2010-06-16 CN claimed
CN-101743226-B Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2012-10-10 CN disclosed
US-7790711-B2 Inhibitors of 11β-Hydroxysteroid Dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-09-07 US disclosed
CN-101743226-A Inhibitors of 11beta-hydroxysteroid dehydrogenase HOFFMANN LA ROCHE 2010-06-16 CN disclosed
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase GILLESPIE PAUL 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase HSD17B1, HSD17B2, HSD11B1 MAPT 4135/4885RAB9A 1754/4885NPC1 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.